Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Ethris has secured a €30M investment from the European Investment Bank to advance the clinical development of its respiratory mRNA products.

PRIVATESep 11, 2026•about 3 hours ago

Amount Raised

€30 Million

Round Type

Venture - Series Unknown

Munich

Investors

European Investment Bank

Description

Ethris, a Munich-based provider of a platform for RNA therapeutics and vaccines, received a €30M investment. The company intends to use the funds to advance the clinical development of its portfolio of respiratory mRNA products. Led by CEO Carsten Rudolph, Ethris utilizes proprietary RNA technology platforms for therapy development. The platform aims to induce mucosal innate immune defense responses at virus entry sites.

Company Information

Company

Ethris

Location

Munich, Bavaria, Germany

About

Ethris has paved a new path from genes to therapeutic proteins, using its proprietary messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilised mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines against viral infections, with the ultimate goal of improving patients' lives.

Don't miss Ethris's next move

Get an email the moment Ethris raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Ethris's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Ethris raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.